ZIXIONG WANG
Scientist Merck & Co.
Zixiong Wang (Mervin) is a Scientist in the Department of Quantitative Biosciences (QB) at the Merck Boston site. He completed both his undergraduate and graduate studies at Boston University. Under the mentorship of Dennis Jones, PhD, Associate Professor in the Department of Pathology & Laboratory Medicine, he conducted research focused on T cell trafficking within tumors and the generation of CAR-T cells. After joining Merck, Mervin has supported multiple QB programs and developed extensive expertise in assay development using organoids and tumoroids. He has also contributed to the development of high-throughput drug screening platforms utilizing tumoroid models.
Seminars
Thursday 30th July 2026
Development of a Tumoroid Screening Platform to Empower Oncology Drug Development
3:00 pm
- Spotlighting strategies to build a robust tumoroid platform capable of growing large volume 3D cultures in 24 well formats, enabling scalable expansion and consistent generation of physiologically relevant tumor microtissues
- Deploying high throughput compound screening across diverse tumoroid panels, capturing heterogeneity in growth, drug response and pathway dependency to rapidly identify promising agents
- Demonstrate the translational value of tumoroid models, showing how their architecture, cellular diversity and treatment responses more closely reflect patient tumors – and how these insights improve early decision making in oncology pipelines
